about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

No­vo touts ear­ly da­ta for next-gen oral weight loss drug as it out­lines next steps

Last year
R&D
Pharma

GSK de­clares sec­ond PhI­II win for Blenrep com­bo in bid to re­vive drug

Last year
R&D

Bay­er on job cuts, pipeline gaps, obe­si­ty and Mon­san­to lit­i­ga­tion as ex­ecs de­fend keep­ing cur­rent struc­ture

Last year
R&D
Pharma

Bay­er says no breakup ‘for now,’ fo­cus­es in­stead on fix­ing ‘bad­ly bro­ken’ ar­eas 

Last year
Pharma

Eli Lil­ly’s Alzheimer’s trek; No­vo Nordisk puts down US roots; Sarep­ta and gene ther­a­py ac­cel­er­at­ed ap­provals; ...

Last year
Weekly

As­traZeneca bails on rox­adu­s­tat’s fu­ture in the US, but keeps Chi­na pact with Fi­bro­Gen

Last year
Deals

Ab­b­Vie’s next CEO; $100B club re­fresh; Top 100 VCs, 2023; More hope for CAR-T in au­toim­mune; and more

Last year
Weekly

Re­searchers de­tail da­ta from first 15 au­toim­mune dis­ease pa­tients treat­ed with CAR-T — and out­stand­ing ques­tions

Last year
R&D
Cell/Gene Tx

Io­vance's $211M of­fer­ing; Almi­rall li­cens­es No­vo drug; As­traZeneca files Da­to-DXd; Sonata lay­offs

Last year
News Briefing

Gilead­'s $4.3B liv­er bet; WuXi un­der fire; Ex­sci­en­tia CEO’s ouster; Late Fri­day cell ther­a­py ap­proval; and more

Last year
Weekly

Ahead of share­hold­er vote on SQZ as­set sale and liq­ui­da­tion, founder Ar­mon Sharei says he will vote yes

Last year
People
R&D

Ot­su­ka’s fixed-dose com­bo dis­ap­points in PhI­II tri­al for Alzheimer’s ag­i­ta­tion

Last year
R&D

No­vo Hold­ings’ $16.5B bid for Catal­ent; No­var­tis’ $2.9B bolt-on; End­points Slack in­ter­view with John Evans; and ...

Last year
Weekly

Syn­log­ic reach­es end of the road for syn­thet­ic bi­ol­o­gy quest af­ter piv­otal da­ta dis­ap­point

Last year
People
R&D

I-Mab Bio­phar­ma to split US, Chi­na busi­ness­es to cut costs, mit­i­gate po­ten­tial risks

Last year
Deals
China

Rare dis­ease biotech Rally­bio cuts 19 staffers and sheds part­nered pre­clin­i­cal pro­grams

Last year
People

Up­dat­ed: No­vo Hold­ings pays $16.5B to take Catal­ent pri­vate — and sells three man­u­fac­tur­ing sites to No­vo Nordisk

Last year
Deals
Manufacturing

End of Aduhelm’s road; Janet Wood­cock ex­it in­ter­view; Stu­art Schreiber's $500M ex­per­i­ment; Ver­tex's pain ...

Last year
Weekly

Take­da wa­gers $300M on Pro­tag­o­nist’s PhI­II rare dis­ease drug

Last year
Deals

‘Watch this evolve’: Sanofi con­tin­ues to talk up its R&D bet as Paul Hud­son wel­comes new CFO

Last year
R&D
Pharma

Up­dat­ed: No­var­tis ax­es blood can­cer drug af­ter PhI­II flop, cau­tions on obe­si­ty FO­MO

Last year
R&D
Pharma

Sanofi's $1.7B rare dis­ease gam­bit; CAR-T boxed warn­ing saga; New biotechs on Nas­daq; A sell­er's mar­ket for M&A?; and ...

Last year
Weekly

Up­dat­ed: FDA’s safe­ty re­view on CAR-Ts cul­mi­nates in new boxed warn­ings of sec­ondary can­cer

Last year
Pharma
Cell/Gene Tx

Sanofi wades in­to AATD in $1.7B bid for In­hi­brx's rare dis­ease drug

Last year
Deals
R&D
First page Previous page 2345678 Next page Last page
A service from the Financial Times